CIK 0001314102 · Non-accelerated filer<br>Smaller reporting company
EyePoint, Inc.
Sign in to watch- Ticker
- EYPT
- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 262774444
- Phone
- 617-926-5000
- Business address
- 480 PLEASANT STREET, SUITE C400, WATERTOWN, MA, 02472
- Former names
- EyePoint Pharmaceuticals, Inc., pSivida Corp., pSivida LTD
- Open-market buys, last 90 days
- $52,258
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$52,258. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-23 | Lurker Nancy Executive Vice Chair | Sale 10b5-1 | −5,044 | $24.97 | $126K | 165,397 |
| 2024-01-23 | Jones David Scott SVP & Chief Commercial Officer | Option exercise | +400 | $12.90 | $5K | 38,362 |
| 2024-01-23 | Jones David Scott SVP & Chief Commercial Officer | Option exercise | +500 | $3.26 | $2K | 38,862 |
| 2024-01-23 | Jones David Scott SVP & Chief Commercial Officer | Sale | −400 | $25.00 | $10K | 38,462 |
| 2024-01-23 | Jones David Scott SVP & Chief Commercial Officer | Sale | −500 | $25.00 | $13K | 37,962 |
| 2024-01-23 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) | −400 | 24,225 | ||
| 2024-01-23 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) | −500 | 91,155 | ||
| 2024-01-22 | Jones David Scott SVP & Chief Commercial Officer | Option exercise | +28,750 | $10.13 | $291K | 66,712 |
| 2024-01-22 | Jones David Scott SVP & Chief Commercial Officer | Option exercise | +5,416 | $11.47 | $62K | 72,128 |
| 2024-01-22 | Jones David Scott SVP & Chief Commercial Officer | Sale | −5,416 | $22.24 | $120K | 66,712 |
| 2024-01-22 | Jones David Scott SVP & Chief Commercial Officer | Sale | −28,750 | $22.69 | $652K | 37,962 |
| 2024-01-22 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) | −5,416 | 4,584 | ||
| 2024-01-22 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) | −28,750 | 31,250 | ||
| 2024-01-11 | Ocumension Therapeutics Director | Sale | −1,910,500 | $19.45 | $37.2M | 100,221 |
| 2024-01-11 | Liu Ye Director | Sale | −1,910,500 | $19.45 | $37.2M | 100,221 |
| 2024-01-11 | Cormorant Asset Management, LP 10% owner | Purchase | +750,000 | $19.75 | $14.8M | 6,893,235 |
| 2024-01-09 | Cormorant Asset Management, LP 10% owner | Purchase | +105,000 | $21.32 | $2.2M | 6,143,235 |
| 2024-01-08 | Paggiarino Dario A. Chief Medical Officer | Option exercise 10b5-1 | +22,913 | $3.26 | $75K | 59,418 |
| 2024-01-08 | Paggiarino Dario A. Chief Medical Officer | Sale 10b5-1 | −22,913 | $21.13 | $484K | 36,505 |
| 2024-01-08 | Paggiarino Dario A. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −22,913 | 68,742 |
Page 16 of 18 · 352 trades